Alethiomics

Developer of targeted therapies to treat blood cancer

placeOxford, England, United Kingdom calendar_todayFounded 2021 groups3 employees language alethiomics.com

Registered entities

Innovation

1 patent family; filing pace active.

YearFilings
20251

Social engagement

Social engagement: 1.8K social following, 10 posts in the last 12 months — below the industry typical range.

Investor mix

2 investors on record.

Investor typeCountShare
Venture capital150%
Other / undisclosed150%

Recent activity

17 Jun 2026
Recognition
13 May 2026
Event
European Hematology Association (EHA) 2026 Congress
16 Apr 2026
Product launch
ATX011
Coming soon